What is it about?

Intention is to foster the initial benefit of biologic agents in ulcerative colitis.

Featured Image

Why is it important?

Should we combine biologic agents and immunomodulators in ulcerative colitis ? And which one to consider or not to favor to increase the therapeutic efficacy of the first one ? Is it of benefit for each biologic agents ?


Specific patients, notably those who initially slowly or less response to biologic agents, not only when anti-biologics antibodies are expressed, immunomodulators may favor innate and adaptive immune benefits.

Philippe Pinton
Ferring Pharmaceuticals

Read the Original

This page is a summary of: Combination of vedolizumab and immunomodulators in ulcerative colitis, Journal of Gastroenterology and Hepatology, September 2021, Wiley,
DOI: 10.1111/jgh.15686.
You can read the full text:



The following have contributed to this page